Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM03 in Rheumatoid Arthritis
NCT04704492Phase 1Completed
- Sponsor
- SinoMab BioScience Limited
- Start
- Aug 2012
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of suciraslimab in rheumatoid arthritis (RA), sponsored by SinoMab BioScience Limited. Primary endpoints: Area Under the Concentration Time Curve (AUC0-t), Time to Maximum Plasma Concentration at Week 2 and 3 more. Started Aug 2012; status: completed.
02
Drugs
suciraslimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04704492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04704492.